Arrowpoint Investment Partners Singapore Pte. Ltd. Takes $317,000 Position in Twist Bioscience Corporation $TWST

Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in Twist Bioscience Corporation (NASDAQ:TWST) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 9,992 shares of the company’s stock, valued at approximately $317,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Royal Bank of Canada raised its position in Twist Bioscience by 11.8% during the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after purchasing an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after purchasing an additional 3,181 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Twist Bioscience by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after purchasing an additional 37,577 shares in the last quarter. Intech Investment Management LLC raised its position in Twist Bioscience by 18.9% during the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after purchasing an additional 4,591 shares in the last quarter. Finally, Norges Bank acquired a new position in Twist Bioscience during the second quarter valued at approximately $737,000.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $73.93 on Friday. The firm’s fifty day moving average price is $56.73 and its two-hundred day moving average price is $45.71. The stock has a market cap of $4.60 billion, a PE ratio of -55.59 and a beta of 2.23. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $80.50. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The company had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.66) EPS. On average, equities analysts expect that Twist Bioscience Corporation will post -1.86 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Robert Chess sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $47.00, for a total value of $470,000.00. Following the sale, the director owned 21,084 shares of the company’s stock, valued at $990,948. The trade was a 32.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Adam Laponis sold 4,000 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $60.00, for a total transaction of $240,000.00. Following the completion of the sale, the chief financial officer directly owned 118,694 shares in the company, valued at approximately $7,121,640. This represents a 3.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 42,768 shares of company stock valued at $2,390,888 over the last quarter. 3.08% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

TWST has been the subject of several research analyst reports. Barclays boosted their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Leerink Partners set a $80.00 price objective on shares of Twist Bioscience in a research report on Friday, May 22nd. Finally, Guggenheim boosted their target price on shares of Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $58.00.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.